Prospective, Randomized (1:1), Open Label, Parallel Group, Active Controlled, Multicenter Study to Assess Safe and Effective Doses of Kabiven (Amino Acids, Electrolytes, Dextrose and Lipid Injectable Emulsion) in Pediatric Patients 2 to 16 Years of Age

Gender
Any

Age Group
Any

At a Glance

IRB#IRB16-0044

Lead PhysicianTimothy A. Sentongo

Collaborator(s)N/A

EligibilityNot Recruiting